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Purpose: To study the effects of a neutralizing antibody to vascular endothelial growth factor (VEGF), given as an
intravitreous injection, on intravitreous neovascularization (IVNV) and ongoing vascular development of avascular retina
in a rat model relevant to human retinopathy of prematurity.
Methods: Newborn Sprague-Dawley rats were exposed to oxygen fluctuations alternating between 50% O2 and 10%
O2 every 24 h. At postnatal day (p)12, rat pups received intravitreous injections of a neutralizing antibody to VEGF or
control nonimmune rat IgG in one eye and were returned to oxygen cycling until p14, at which time they were placed into
room air. At p18 (time of maximal IVNV) or p25 (time point in regression), animals were sacrificed. Their retinas were
dissected, flat mounted, and stained with Alexa-isolectin for fluorescence microscopy. IVNV was measured as number
of clock hours involved in injected VEGF antibody and control eyes. Mean clock hours of IVNV, avascular/total retinal
areas and capillary densities within vascularized retinas were determined in injected eyes of control and treatment groups.
Mean clock hours of IVNV in fellow noninjected eyes from control and treatment groups were analyzed by Student’s t-
tests to assess possible crossover effects from systemic absorption of antibody. Eyes from p13 rat pups were sectioned
for immunohistochemistry or analyzed for VEGF receptor 2 (VEGFR2) phosphorylation by western blot. Free retinal
VEGF at p13, one day following injections, was measured by ELISA.
Results: Neutralizing antibody to VEGF at 25 ng and 50 ng caused a modest but significant inhibition of IVNV compared
to IgG injected controls at p18, but only the 50 ng dose decreased IVNV compared to control at p25 (one-way ANOVA
p=0.003; posthoc Bonferroni t-test p=0.003). Neither dose caused a significant difference in avascular/total retinal area
at p18 compared to control. However, at p25, the 50 ng dose caused a significant reduction in avascular/total retinal area
compared to the 25 ng dose (ANOVA p=0.038; posthoc Student’s t-test p=0.038). There was no difference in avascular/
total retinal area between IgG and the 25 ng dose. At p13, qualitative analysis of immunohistochemical sections of retina
showed the 50 ng dose of VEGF antibody reduced VEGFR2 phosphorylation within the retina and around blood vessels.
Also at p13, there was a significant increase in free intraretinal VEGF protein in eyes that had been treated with 50 ng
dose of VEGF antibody compared to IgG injected control (Student’s t-test p=0.042). There were no differences in capillary
densities in the vascularized retinas between eyes injected with the 50 ng dose of VEGF antibody and IgG control. There
was also no difference in weight gain between treated and control groups.
Conclusions: Neutralizing antibody to VEGF at a 50 ng dose caused a significant and sustained reduction in IVNV without
interfering with ongoing retinal vascularization in a rat model of ROP, whereas a lower dose of antibody did not. These
data also suggest that compensatory regulatory mechanisms may lead to increased VEGF concentration after intravitreous
injection of a neutralizing antibody to VEGF. Further study is necessary for safety and for determination of drug dose of
VEGF antibody, since dose of treatment appears important and may vary among infants with severe ROP. In this study,
survival of already developed retinal capillaries did not appear affected. Neutralizing VEGF by an intravitreous injection
of antibody may offer a treatment consideration for severe ROP, which fails current standard of care management.
Retinopathy of prematurity (ROP) is a leading cause of
childhood blindness worldwide [1]. An important feature of
the pathology in ROP is intravitreous neovascularization
(IVNV), which develops at the junction between avascular
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and vascular retina. The IVNV grows into the vitreous gel
rather than into the retina, bleeds and with fibrovascular
contraction, leads to retinal detachment and blindness [1,2].
Years ago, a hypothesis was put forth that the hypoxic
and avascular retina in diseases like ROP released an
angiogenic factor that caused pathologic angiogenesis to
develop and appear as IVNV [3-5]. Among several angiogenic
factors, vascular endothelial growth factor (VEGF) has
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345emerged as one of the most important in the development of
IVNV [6,7]. VEGF is upregulated by hypoxia and ischemia
[8,9] and is increased in the serum and vitreous of patients
with diseases characterized by IVNV [10]. In addition, IVNV
has been reduced in experimental models in which the action
of VEGF was inhibited through addition of soluble receptors
[11], antibodies to VEGF receptor-2 (VEGF-R2) [12],
oligonucleotides [13], or aptamers [14]. In human adults,
agents that inhibit the bioactivity of VEGF have dramatically
reduced ocular morbidity in several neovascular eye diseases,
including diabetic retinopathy and age-related macular
degeneration [15-17].
Since the current management for acute severe ROP is
ablation of the peripheral avascular retina with laser or
cryotherapy [18,19], the question arises whether an agent that
inhibits the biologic activity of VEGF would be more effective
and less destructive than the current management. A few case
series have been reported on short-term effects of anti-VEGF
agents in acute ROP [20,21]. However, VEGF is essential for
normal retinal vascular development [22-25], and is an
endothelial and neuronal survival factor [26,27]. Since retinal
vascular development is ongoing in the premature infant,
several questions remain before considering treatment of ROP
with agents that inhibit the actions of VEGF. First, would
inhibition of VEGF reduce IVNV without interfering with
ongoing retinal vascularization? A previous study using the
mouse model of hyperoxia-induced vasoobliteration and
revascularization showed that a neutralizing antibody to
VEGF interfered with preretinal endothelial budding but
appeared to allow revascularization into the previously
hyperoxia-induced obliterated retina [28]. The authors,
however, noted that they were unable to measure the area of
avascular retina in the mouse model. Also, the mouse model
uses high constant oxygen, which is not as relevant to most
cases of human ROP in the U.S.today.
Second, would inhibition of VEGF compromise newly
developed retinal vasculature or have adverse effects from
systemic absorption? To address these questions, we used the
Penn “50/10” oxygen-induced retinopathy (OIR) model [29]
to test a neutralizing antibody to VEGF (VEGFab), which has
a mechanism of action similar to current treatments used in
adult eye disease [17].
The oxygen extremes in the Penn 50/10 OIR model [29]
were found to be similar to the transcutaneous oxygen levels
measured in a premature infant that developed severe ROP
[30], as inspired oxygen levels rat pups breathe directly
correlate with rat arterial oxygen levels (PaO2) [29]. Also,
rather than the constant oxygen used in other models [12,
31-34], the 50/10 OIR model exposed pups to fluctuations in
oxygen, a risk factor for severe ROP [30,35,36]. Finally, the
50/10 OIR model reproducibly and consistently developed
IVNV and avascular retina similar in appearance to acute
Stage 3 ROP [29,37] and underwent natural regression of
IVNV with later vascularization of the previously avascular
retina. The outcomes are quantifiable: IVNV at the junction
of vascular and avascular retina; the percent peripheral
avascular/total retinal area; and the number of capillary
junctions within an area of vascularized retina (capillary
density). The features of the 50/10 OIR model made it relevant
to ROP and useful to evaluate our research hypotheses. We
found that of the doses of VEGFab tested, the 50 ng dose
sustained inhibition of IVNV and did not interfere with
ongoing vascularization of the retina. We also found no
adverse effect on the density of newly formed retinal
capillaries in vascularized retina or evidence of an adverse
effect from systemic absorption. However, one day following
intravitreous injection of antibody to VEGF qualitatively
reduced intraretinal VEGFR2 phosphorylation and caused an
increase in the retinal concentration of free VEGF compared
to control.
METHODS
All animal studies complied with the University of North
Carolina’s Institute for Laboratory Animal Research (Guide
for the Care and Use of Laboratory Animals) and the ARVO
Statement for the Use of Animals in Ophthalmic and Visual
Research.
Animal model of retinopathy of prematurity: Litters of
12–14 newborn Sprague-Dawley rat pups, postnatal age 0
(p0), with their mothers (Charles River, Wilmington, MA)
were placed into an Oxycycler incubator (Biospherix, New
York, NY), which cycled oxygen between 50% O2 and 10%
O2 every 24 h. At p14, the pups were returned to room air for
4 or 11 days [29]. Carbon dioxide in the cage was monitored
and flushed from the system by maintaining sufficient gas-
flow. The pups developed IVNV at p18 [38] and regression
of IVNV with vascularization of the previously avascular
retina at p25-p30 [29].
Neutralizing VEGF bioactivity: VEGFab, a neutralizing
antibody to VEGF164 that recognizes rat (R & D Systems,
Minneapolis MN) was administered as an intravitreous
injection at doses of 25 or 50 ng/μL. Nonimmune rat IgG was
used as a control (R & D Systems).
Intravitreous injections: Rat pups were anesthetized with
an intraperitoneal injection of a mixture of 20 mg/kg ketamine
and 6 mg/kg xylazine (both from NLS Animal Health,
Pittsburgh, PA). A topical anesthetic (0.5% tetracaine
hydrochloride) was administered before inserting a 30-gauge
needle just posterior to the limbus to avoid lens damage. One
µL injections were performed in right eyes using a Hamilton
syringe. We then applied 0.5% topical erythromycin ointment
(Fougera, Melville NY) to the injected eye. All fellow eyes
were not injected. Animals were monitored until recovery (~2
h) and then returned with their mothers to the Oxycycler for
two more days. At p14, each litter was removed from the
Oxycycler and placed into room air until p18 or p25. All pups
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346were weighed at the times of injection and sacrifice. Mean
weights of treated and control pups were determined.
Dissecting retinal tissue for flat mounting and
cryosections: Pups were anesthetized at either p13 for
immunohistochemical staining or p18 or p25 for retinal flat
mounts by intraperitoneal injection of 60 mg/kg ketamine and
18 mg/kg xylazine. We directly perfused 1.0 mL
paraformaldehyde (0.5%) into the left ventricle before
euthanasia by intracardiac injection of 50 μl pentobarbital (80
mg/kg). Both eyes were enucleated and fixed in 2%
paraformaldehyde for 2 h. Using a modification of the method
of Chan-Ling [39], the anterior segments were removed and
the retinas with intact ora serratas were dissected and placed
into PBS after removal of the hyaloidal vessels and any
remaining vitreous. Four incisions were made 90 degrees
apart. The retinas were flattened and then placed onto
microscope slides. For cryosections, intact fixed eyes with
only the cornea, lens, and vitreous removed were put into 30%
sucrose/PBS overnight. Each eye was blotted with filter paper
to remove excess liquid, soaked in optimal cutting
temperature compound (Tissue-Tek, Torrance, CA) and kept
at −80 °C for future analysis.
Tissue staining: To stain the retinal vasculature, the
flattened retinas were permeabilized in ice-cold 70% v/v
ethanol for 20 min, then in PBS/1% Triton X−100 for 30 min,
and then incubated with 5 μg/ml Alexa Fluor 568 conjugated
G. simplicifolia (Bandeiraea) isolectin B4 (Molecular Probes,
OR) in PBS overnight at 4 °C. Each slide was rinsed three
times in PBS, mounted in PBS:glycerol (2:1) with
VectaShield (Vector Labs, CA), and protected with a
coverslip, which was then sealed with nail varnish. Images of
the retinal blood vessels were captured using a Nikon
TE2000U inverted microscope (Michael-Hooker Microscopy
Facility, University of North Carolina, Chapel Hill) and
digitally stored for analysis. Image sections were assembled
using methods that maintained the original image dimensions
and that did not induce image distortion using Tekmate’s
PhotoFit Premium v1.44 (Tekmate, Tokyo, Japan) or with
Adobe Photoshop 7.0 (Adobe Systems, San Jose, CA).
Figure 1. Lectin-stained flat mounts of
retinas in pups exposed to oxygen-
induced retinopathy or room air at p18
and p25. A: Rat pups exposed to the
50/10 oxygen-induced retinopathy
(OIR) model developed IVNV at the
junctions of vascular and avascular
retina after return to room air (RA).
Retinal flat mounts were made and
stained with isolectin to reveal the
retinal vasculature and intravitreous
neovascularization (IVNV) at the
junction of vascular and avascular retina
at p18 in 50/10 oxygen-induced
retinopathy (50/10 OIR)(A) or room air
(RA) B: Lectin-stained retinal flat
mount from a p18 RA rat pup. C, D:
Lectin-stained retinal flat mounts from
OIR (C) and RA (D) pups at p25. An
example of IVNV has been enlarged for
clarity (inset, A).
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347Eyes—Eyes frozen in optimal cutting temperature
compound were cut into 10-μm sections, adjacent to or within
10 μms of one another. For qualitative comparisons, we placed
all labeled serial sections on the same microscope slide to
assure equal handling and antibody labeling conditions.
Sections were first incubated in PBS/1% Triton X-100 for 30
min. Some retinas were incubated with Alexa Fluor 568-
isolectin B4 in PBS for 30 min at room temperature to stain
the vasculature. Retinas were washed in PBS three times
before they were incubated for 30 min in 3% normal goat
serum to block nonspecific binding of the primary antibody.
Antiphospho-VEGFR1 (Upstate, Lake Placid, NY) and
antiphospho-VEGFR2 (Santa Cruz Biotechnology, Santa
Cruz, CA), both polyclonal rabbit antibodies specific for rat
protein, were used at a dilution of 1:100. Retinas were
incubated for 60 min at room temperature. After three washes
in PBS, retinas were incubated for 20 min with a 1:500 dilution
of goat antirabbit conjugated with Alexa-488 (Invitrogen,
Carlsbad, CA). All retinal cryosections were rinsed three
times in PBS, then some were incubated with a 1:5,000
dilution of Hoechst 33342 (Invitrogen) for 15 min, and all
were mounted in PBS-glycerol (2:1 with VectaShield; Vector
Laboratories). Some sections were stained without the
primary antibody as a negative control to observe possible
nonspecific binding. On all slides, the coverslips were sealed
with nail polish, and images of the sections were captured with
a Leica SP2 scanning laser confocal microscope (Leica,
Wetzlar, Germany) and digitally stored for analysis. Analysis
was qualitative and based on a scale: 0 – none; 1+ weakly
present; 2+ strongly present.
Measurement of intravitreous neovascularization: To
determine the extent of IVNV, retinal images from injected
and fellow noninjected eyes from experimental and control
groups were randomized, labeled, and analyzed for IVNV
clock hours. Two masked reviewers performed all analyses.
The presence of IVNV was determined with a technique
adapted from those used in clinical trials [18] and animal
model determination [40]. Flat mounts were divided into 12
clock hours of approximately equal area using Adobe
Photoshop, assessed for the presence of IVNV [18,40], and
assigned a number (0 to 12) based on the number of clock
hours exhibiting IVNV.
Analysis of peripheral avascular areas and
quantification of capillary density: Digitized images of the
total retinal area and peripheral avascular areas were measured
(ImageTool v.3, University of Texas, San Antonio, TX). The
peripheral avascular area was expressed as a percentage of the
total retinal area for experimental and control eyes. Central
capillary density was quantified as the summation of capillary
junctions (crossings) within four equal square areas, each
0.16 mm2, in each of the four quadrants of the vascularized
retina and expressed as number of junctions per 0.64 mm2
using ImageTool [37].
Fresh tissue preparation: Animals were euthanized with
an 80 mg/kg intraperitoneal injection of pentobarbital. Both
eyes were enucleated, and the retinas were isolated under a
dissecting microscope in similar fashion as for flat mounting,
except that the ora serratas were removed. The tissue was
placed into modified radioimmuno precipitation assay (RIPA)
buffer (20 mM Tris base, 120 mM NaCl, 1% Triton X-100,
0.5% sodium deoxycholate, 0.1% SDS, 10% glycerol) for
ELISA and frozen at −20 °C until analysis. For one litter (12
rat pups), the cornea and lens were removed bilaterally, and
the vitreous then was collected from the eye-cup to avoid
contamination from blood before removal of retinas for
Figure 2. VEGF concentration increased in the 50/10 oxygen-induced retinopathy model compared to room air. A: Vascular endothelial growth
factor (VEGF). VEGF concentration was increased in the 50/10 oxygen-induced retinopathy (OIR) model compared to RA at all time points
(overall ANOVA p<0.001; post-hoc Student’s t-tests * p<0.001). In 50/10 OIR model, VEGF concentration at p14 was greater than at p12 or
18 (ANOVA p<0.001; posthoc Student’s t-tests, * p<0.001; n=6 for each time point). B: VEGF concentration was measured by ELISA in the
retina (204.5±12.4 pg/mg) and vitreous (15.7±4.3 pg/mg) of p18 OIR-raised rat pups (n=12 for 50/10 OIR and RA).
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348analyses. Vitreous samples from each animal were pooled in
pairs, put into RIPA and analyzed for VEGF by ELISA.
Western blot for phosphorylation of VEGF receptors 1
and 2: Freshly dissected unfixed retinal tissue immersed in
modified RIPA buffer with a 1:100 protease inhibitor cocktail
(Sigma, St. Louis, MO) were homogenized, and lysates
centrifuged at 13,000xg for 15 min at 4 °C. The supernatants
were collected, and total protein was quantified by
bicinchoninic acid (BCA) assay according to the
manufacturer’s protocol (Pierce, Rockford, IL). Next 75 μg
protein samples were immunoprecipitated overnight with 2
μg of a polyclonal antibody to VEGFR-2 (Santa Cruz
Biotechnology). The immune complexes were then bound to
Sepharose G Protein beads for 1 h before they were washed
three times with RIPA buffer. The protein-sepharose complex
was eluted in 2x sample buffer (Laemmli sample buffer with
5% β-mercaptoethanol), boiled and run by SDS–PAGE. After
transfer to polyvinylidene fluoride (PVFD) (Millipore,
Billerica, MA) using standard protocols, the blots were
blocked in 5% bovine serum albumin/Tris-buffered saline
with Triton X-100 (BSA/TBST) for 1.5 h at room temperature,
then incubated in a 1:1000 dilution of antiphospho-VEGFR-2
(Santa Cruz Biotechnology) antibody overnight with gentle
agitation at 4 °C. Blots were washed four times in TBST buffer
then incubated 1 h with horseradish peroxidase (HRP)-
conjugated secondary antibody and washed with TBST.
Immunoreactive proteins were detected with Immobilon
Western chemiluminescence (Millipore) and analyzed with
Un-scan-it v6 (Silk Scientific, Orem, UT).
ELISA of VEGF: Frozen vitreous and retinal tissue stored
in modified RIPA buffer with protease inhibitor cocktail were
homogenized, thawed, and subjected to centrifugation at
13,000xg for 10 min at 4 °C. Total protein was quantified
using a BCA assay according to the manufacturer’s protocol
(Pierce). Supernatants were then assayed without dilution in
duplicate using a commercially available ELISA kit, raised
against rat VEGF164 isoform (R& D Systems).
Statistical analysis: For individual experiments and as
groups based on condition and time point of analysis, the
magnitude of within subject effects was assessed by Student’s
t-tests that compared clock hours of IVNV from noninjected
eyes of treatment and control groups. In cases with more than
two treatment groups analyzed, one-way ANOVA was
performed with posthoc Bonferroni correction. Each group
Figure 3. Clock hours of intravitreous
neovascularization and avascular/total
retinal areas of lectin-stained retinal flat-
mounts from rat pups in 50/10 oxygen-
induced retinopathy after intravitreous
injection of neutralizing antibody to
vascular endothelial growth factor
(VEGFab) or control nonimmune rat
IgG. A: Mean clock hours of
intravitreous neovascularization
(IVNV)at p18 were significantly
decreased by injection of either 25 ng or
50 ng VEGFab compared to IgG control
(ANOVA p<0.001; * posthoc Student’s
t-tests p<0.001 compared to IgG). B:
Mean clock hours of IVNV at p25 were
significantly decreased by injection of
50 ng VEGFab compared to IgG control
(ANOVA p=0.003; * posthoc Student’s
t-test p=0.003). C: Peripheral avascular/
total retinal area was no different in
retinas treated with either VEGFab dose
compared to IgG control at p18
(ANOVA p=0.238). D: At p25, the
overall ANOVA for peripheral
avascular/total retinal area was
significant (p=0.038). Posthoc testing
showed the 50 ng dose of VEGFab was
significantly decreased compared to the
25 ng dose (* posthoc Student’s t-test,
25 ng versus 50 ng, p=0.038). However,
neither dose of VEGFab was
significantly different to control IgG.
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349compared in flat mount analysis had at least 12 or more pups
from at least two litters. The magnitude of treatment effect on
bodyweight gain was assessed by comparison of the mean
bodyweights between treated and control groups assayed at
the same time point by Student’s t-tests. For all comparisons,
an alpha level of <0.05 was used as the criterion of
significance.
RESULTS
Model of retinopathy of prematurity (50/10 oxygen-induced
retinopathy model): From all experiments, mean clock hours
of IVNV and percent avascular retina were determined for the
fellow noninjected eyes of pups exposed to the 50/10 OIR
model. At p18, 8 ±0.9 (mean±S.E.) clock hours of IVNV and
19.3% ±4.0% (mean±S.E.) avascular/total retinal area were
present. At p25, 4 ±1.0 (mean±S.E.) clock hours of IVNV and
7.8% ±1.9% (mean±S.E.) avascular/total retinal area were
present. In comparison, flat mounts for room-air-raised pups
at p18 and p25 had no IVNV and had fully vascularized retinas
(Figure 1A-D). Others have reported the time point for
maximum IVNV in the 50/10 OIR model to be p20 [38].
However, we measured IVNV clock hours from 2 noninjected
litters of pups exposed to the 50/10 OIR model and assayed
at either p20 or p18 and found no difference in mean values
[t test, p=0.2059; mean clock hours 5.1 +3.7 (p20, n=12) and
7.07+2.8 (p18, n=12)]. For all subsequent experiments, we
used p18 as the time point to analyze IVNV and p25 as a time
point during regression of IVNV and ongoing vascularization
of previously avascular retina.
We previously found that VEGF164 mRNA was the only
isoform that was upregulated by repeated oxygen fluctuations,
a risk factor for severe ROP [41]. We therefore determined
the effect of fluctuations in inspired oxygen on VEGF protein
measured by ELISA in whole retinas at different time points
in the 50/10 OIR model. The ELISA kit uses an antibody
Figure 4. VEGFR2 phosphorylation was decreased by injection of 50 ng VEGFab. Vascular endothelial growth factor receptor 2 (VEGFR2)
phosphorylation was noted mainly at the ganglion cell/nerve fiber layer and superficial and deep retinal vessels in noninjected and IgG injected
controls (2+, upper left). Phosphorylation of VEGFR2 was reduced after injection with 50 ng VEGFab (1+, lower left). VEGFR1
phosphorylation was noted at the ganglion cell/nerve fiber layer and outer plexiform layer in noninjected and IgG injected controls (2+, upper
right). No change noted in 50 ng VEGFab-injected eyes (2+, lower right). All injections were performed at p12 and eyes removed at p13.
Green indicates phosphorylated VEGFR1 or phosphorylated VEGFR2; red indicates lectin-stained vasculature. Central retina is toward the
optic nerve, and peripheral retina is within vascularized retina near the junction with avascular area.
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350raised against full length VEGF164. Although this assay does
not discriminate among the VEGF isoforms, the most likely
isoform is VEGF164, because we previously found it to be the
predominant isoform expressed at the time of maximum
IVNV in the 50/10 OIR model [41]. VEGF protein was
significantly increased in the 50/10 OIR model compared to
room air at p12, p14, and p18 (ANOVA test p<0.001; Figure
2A). In addition, posthoc Bonferroni analysis revealed a
significant increase in VEGF at p14 compared to either p12
or p18 (p<0.001; Figure 2A), similar to that reported by others
using this model [38]. We also measured vitreous VEGF at
p18 as 15.7 ± 1.25 pg/mg total protein (mean±S.E.) (Figure
Figure 5. Phosphorylation of VEGFR2
at p18. Phosphorylation of vascular
endothelial growth factor receptor 2
(VEGFR2) in lectin-stained IVNV
(arrow) in p18 in noninjected, IgG
injected and 50 ng VEGFab injected
eyes. There was no qualitative
difference in phosphorylation between
groups.
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3512B), which was at the lower limits of detection for the ELISA
assay.
Neutralizing VEGF reduces intravitreous neovascularization
while permitting vascularization of the previously avascular
retina: Because VEGF protein peaked at p14 in the 50/10 OIR
model, we chose p12 (following a 10% O2 cycle) as the time
point to inject VEGFab or control nonimmune rat IgG. Pups
were then returned to cycling until p14, at which time they
were placed into room air until analysis. At p18, the time point
of maximal IVNV, both the 25 ng and 50 ng doses of VEGFab
caused a significant reduction in clock hours of IVNV
compared to respective concentrations of IgG (ANOVA
p<0.001, posthoc Bonferroni t-tests p<0.001 compared to
IgG, Figure 3A). Since there was no difference in avascular/
total retinal area in clock hours of 25 ng and 50 ng IgG injected
groups, data was collapsed into one IgG control group. There
was no significant difference in avascular/total retinal area
between VEGFab-injected and control groups at p18
(ANOVA, p=0.238, Figure 3C).
At p25, however, only the 50 ng VEGFab dose sustained
the inhibitory effect on IVNV (ANOVA p=0.003; posthoc
Student’s t-test p=0.003, Figure 3B). Furthermore, eyes
injected with 25 ng VEGFab had a slight but insignificant
increase in the number of clock hours of IVNV compared to
control, suggesting that the 25 ng dose may have been
inadequate to sustain an inhibitory effect (Figure 3B). The
overall ANOVA for mean avascular/total retinal area of eyes
injected with any VEGFab dose was significant, and there was
a significant decrease in avascular/total retinal area in the 50
ng VEGFab group compared to 25 ng VEGFab group.
However, there was no difference between either dose of
VEGFab and control IgG at p18 (Student’s t-test, p =0.133)
or p25 (Student’s t-test, p =0.934).
Mean capillary densities measured from vascularized
retina of pups whose eyes had been injected with 50 ng
VEGFab were not different from those injected with control
IgG, (p18, Student’s t-test p=0.133; p25, Student’s t-test
p=0.934). Weight gain of pups from p12 (following a 10%
O2 cycle) to p18 or from p12 to p25 whose eyes were injected
with 50 ng VEGFab were also no different compared to
respective measurements from control injected pups
(Student’s t-tests p>0.05). There was also no apparent cross
over effect from systemic absorption of either dose of
VEGFab when mean clock hours of fellow noninjected eyes
of experimental groups from p18 and p25 were compared to
those of respective control groups (Student’s t-tests all
p>0.05).
Effects of neutralizing vitreous VEGF on VEGF and VEGF
receptor phosphorylation in the retina: To determine the
effects of an intravitreous injection of neutralizing antibody
to VEGF on retinal VEGF and VEGF signaling through its
receptors, VEGFR1 and VEGFR2, we performed
immunohistochemical staining and western blot analysis on
eyes that had been injected with 50 ng VEGFab or control
nonimmune IgG. Cryosections were taken at p13 and were
immunolabeled with antibodies to phosphorylated VEGFR-1
or phosphorylated VEGFR-2. Sections were taken centrally
(toward the optic nerve) and peripherally within vascularized
retina near the junction with avascular retina. In general, in
both noninjected and IgG-injected eyes, VEGFR-2
phosphorylation was present mainly in the ganglion cell and
nerve fiber layers (2+) and around superficial and deep retinal
vessels (2+), whereas VEGFR-1 phosphorylation was present
in the ganglion cell (but not nerve fiber layer) and in the outer
plexiform layer (2+) (Figure 4). VEGFR-2 phosphorylation
was reduced in eyes injected with VEGFab compared to
control (1+) at p13 (Figure 4). There was no change observed
in VEGFR1 phoshorylation from cryosections among treated
control and non-injected eyes (Figure 4). At p18, there was
reduced VEGFR2 phosphorylation in the ganglion cell/nerve
fiber layer regions in all groups (1+) compared to p13 (Figure
5). Phosphorylation (2+) remained strong in blood vessels and
in IVNV at p18 (arrow, Figure 5). There was no difference in
VEGFR2 phosphorylation between noninjected, IgG injected,
and 50 ng VEGFab injected eyes at p18. Despite the findings
on immunohistochemistry, we were unable to detect a
significant difference in phosphorylated to total VEGFR2 in
whole retinas analyzed by western blot from VEGFab injected
(50 ng) and control IgG injected eyes at p13 (Figure 6).
To determine the effect of an intravitreous injection of
VEGFab on free VEGF concentration within the retina, we
Figure 6. Phosphorylated VEGFR2 by Western blot in 50 ng
neutralizing antibody to vascular endothelial growth factor and IgG
injected eyes. No difference in retinal vascular endothelial growth
factor receptor 2 (VEGFR2) phosphorylation to total VEGFR2 from
eyes injected with either 50 ng neutralizing antibody to VEGF
(VEGFab) or control IgG at 12 and assayed at 13 (p=0.648, Student’s
t-test).
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352performed ELISA assays in retinas that had received 50 ng
VEGFab or nonimmune IgG. We first determined if antibody-
bound VEGF was detectible by ELISA testing. We incubated
the same amount of protein from p14 50/10 OIR noninjected
retinas with either 1 µg VEGFab or IgG overnight and
measured the free VEGF within the samples using an ELISA.
We found a decrease in free VEGF measured by ELISA in
VEGFab-treated retina compared to control treated retina,
providing support that ELISA does not detect VEGFab-bound
VEGF (Figure 7A). We then measured free retinal VEGF at
p13 in eyes from pups exposed to the 50/10 OIR model and
that had received intravitreous injections of 50 ng VEGFab or
IgG control injections at p12. VEGF was increased in the eyes
that had been injected with 50 ng VEGFab (mean±S.D.:
234.7±34.2) compared to those injected with IgG (mean
±S.D.: 182.2±34.4) (Figure 7B) (p=0.042, Student’s t-test).
Free vitreous VEGF was below the detectible limits of the
ELISA in both groups.
DISCUSSION
Since the 50/10 OIR model consistently develops IVNV and
naturally undergoes regression of IVNV followed by
vascularization of previously avascular retina, we were able
to test the effects of neutralizing VEGF with antibody on these
quantifiable outcomes by analyzing two different time points.
We found that neutralizing VEGF with an intravitreous
injection of 50 ng of VEGFab administered at p12 caused a
significant reduction in IVNV at p18. Furthermore, this dose
sustained the effect at p25 and did not interfere with ongoing
retinal vascularization. However, the lower dose of antibody
did not sustain the inhibitory effect on IVNV.
Antibodies generally are cleared from that eye over
several days–on average 5.6 days in monkey vitreous [42,
43]. Since vitreous VEGF concentration at p18 was
approximately 1/10 of the retinal VEGF (Figure 2B), we
propose that an adequate dose of VEGFab may neutralize
sufficient vitreous VEGF without severely interfering with
intraretinal signaling necessary for ongoing retinal vascular
development [23,24,44]. If the concentration of antibody
binds both retinal and vitreous VEGF sufficiently to cause
vitreous VEGF bioactivity to be effectively zero, then it is
possible a compensatory increase in intraretinal VEGF
protein, as we found, may promote intraretinal
vascularization. If the level of antibody is too low, then both
IVNV and intraretinal vascularization would be reduced, but
chemoattractive forces in both vitreous and retina may be
insufficient to inhibit, but only slow retinal vascularization.
Indeed, we found a slight, although insignificant, increase in
avascular retina compared to IgG control at p25. Still the
avascular retinal area at p25 was less than that at p18.
There is increasing evidence that the role of VEGF in
retinal vascular development and oxygen stresses is complex.
It has been reported that, a front of migrating cells, e.g.,
astrocytes in cat [24] or angioblasts in dog [45], sense
physiologic hypoxia and express VEGF. The ensuing
endothelial cells are attracted to VEGF and migrate to create
blood vessels [24]. More recently, it has been found that
VEGF concentration may regulate endothelial cell division
rate [46,47], but the presentation of VEGF, as in a gradient,
regulates endothelial tip cells at the migrating front and direct
the growth of endothelial cells [48]. Furthermore, there is
evidence that a gain in VEGF signaling through VEGFR2 can
cause disoriented endothelial daughter cell divisions rather
than orderly angiogenesis [49]. In immunohistochemical
qualitative assessment of immunohistochemical sections
taken from eyes one day after injections, we found that,
compared to control or noninjected eyes, 50 ng of VEGFab
appeared to reduce but not entirely inhibit signaling of
VEGFR2, the receptor believed most associated with
angiogenic processes [50]. Although we were unable to
confirm the reduction in VEGFR2 phosphorylation by
western blot analysis, we suspect that analyzing whole retinas
may dilute effects seen in a small percentage of cells.
VEGFR1 phosphorylation did not appear to be affected. This
may have been because VEGFR1 has greater affinity for
VEGF [50] and would have bound free VEGF not associated
with VEGFab. Effects from VEGFab on intraretinal VEGFR2
signaling appeared to have resolved by p18. We also found
that free VEGF in the retina measured one day after an
injection of 50 ng VEGFab was increased compared to
control. Possibly, this represents a compensatory effect and
may partly explain the insignificant but increased number of
clock hours of IVNV at p25 in eyes injected with 25 ng of
VEGFab when compared to Ig G control.
The VEGFab used in this study is greater than 78kD
molecular weight, which is the limit above which diffusion
beyond the inner plexiform layer becomes extremely slow
[43,51]. From our immunohistochemical sections, much of
the reduction in VEGFR2 phosphorylation appeared to be in
the region of the ganglion cell/nerve fiber layers. However,
there is experimental and clinical evidence that antibodies of
higher molecular weight, including the humanized mouse
monoclonal antibody to VEGF (bevacizumab), penetrate into
the retina and can affect signaling in deeper retinal layers
[52].
Several papers have shown immunolabeling of VEGF
receptors but not phosphorylation, in developing retinal
vessels and in IVNV-like vessels or endothelial buds after
oxygen stress [12,53-55]. VEGFR2 immunoreactivity was
also reported to be strong within IVNV in a beagle model of
OIR and weak within newly forming intraretinal vessels
during normal development [12]. In addition, VEGF and its
receptors were found within neural retina [56-58], mainly the
ganglion cells, astrocytes, and Mueller cells. In development,
VEGF receptor inhibitors led to a reduction in the thickness
of the retina and in the ganglion cell layer [54]. We report that
activation of VEGFR2 signaling was associated with
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353intraretinal and intravitreous blood vessels and within the
ganglion cell and nerve fiber layers of retinas from pups
exposed to the 50/10 OIR model. VEGFR1 phosphorylation
was associated mainly with the ganglion cell and outer
plexiform layers. We propose that inhibition of VEGFR2
signaling by VEGFab occurred in developing vessels, and
within Mueller cell processes, astrocytes, and ganglion cells
at p13, and was resolved by p18. Definitive confirmation of
what cells are affected will require colabeling of retinal
sections in future studies. Although reduced VEGFR2
phosphorylation was associated with decreased IVNV in our
experiments, further study is needed to determine if there are
significant effects on neuronal and glial cells, particularly if
higher doses of VEGFab or prolonged and repeated doses are
considered. However, ganglion cells treated with the VEGF
antibody, bevacizumab, were not reported to have reduced
viability in vitro [59].
Although we found a modest decrease in IVNV compared
to control, it would represent a clinically significant outcome
in reducing the risk of poor vision in preterm infants with ROP
[19]. Many studies have shown that blocking other signaling
pathways can inhibit IVNV more completely [60-62].
However, in ROP, aggressive angiogenic inhibition is not
desired, because ongoing retinal vascular development may
both lead to improved visual function and reduce the hypoxic
stimulus for pathologic IVNV.
The effects of inhibiting VEGF on pathologic IVNV and
its presumed stimulus, the avascular retina, are relevant
questions when considering anti-VEGF strategies for ROP in
which it is undesired to inhibit retinal vascular development
but necessary to prevent or treat IVNV. Our data suggest that
an intravitreous antibody to neutralize VEGF may be effective
and safe, but dose appears important. Determining an
effective dose in individual infant eyes is difficult because
vitreous VEGF protein produced by the hypoxic retina may
vary in separate eyes depending on the zone of ROP--i.e., the
extent of avascular retina. Currently, vitreous VEGF
measurements cannot be obtained safely in human infants
with stage 3 ROP. In our study, measuring vitreous VEGF was
not always possible in the animal model, because the
concentration of VEGF in the vitreous was at the lower limits
of detection by ELISA. Very high concentration or slow
release formulations of an anti-VEGF antibody may carry a
risk to retinal neurons and also theoretically inhibit ongoing
retinal vascular development [22-24,26,27]. In addition, too
low a dose of anti-VEGF antibody may not be effective or
require repeated injections, which increase risk. Furthermore,
unlike in the 50/10 OIR model, human infants with ROP do
not always undergo disease regression, in part, because of the
effect of other factors [1].
When administering an intravitreous injection of any
drug into an infant eye, the high vitreous/blood volume of the
premature infant to the adult must be considered. The resultant
drug concentration from absorption into the systemic
circulation is greater in the infant than that in adult and may
cause systemic effects [37]. Systemic anti-VEGF agents used
in metastatic colon or renal cell carcinoma have been reported
associated with several serious effects, including
hypertension and vascular events [63-65]. In this study,
compared to control injected eyes, we found no adverse effect
on weight gain or on outcomes in the fellow eyes, suggesting
little effect from systemic absorption at the time points we
analyzed. Nor did we find an adverse effect on capillary
densities of newly vascularized retina within the treated eyes.
Although questions remain, in certain severe forms of ROP
Figure 7. Unbound VEGF. A: Retinas from 50/10 oxygen-induced retinopathy (OIR) noninjected pups at p14 were incubated overnight in
either 1 µg neutralizing antibody vascular endothelial growth factor (VEGFab) or IgG. Incubation with VEGFab reduced detectable free
vascular endothelial growth factor (VEGF) compared to control IgG. B: Eyes in 50/10 OIR injected with 50 ng VEGFab at p12 showed
significantly increased free VEGF in the retina at p13 compared to those injected with IgG (n=5). Asterisk (*) indicates p=0.042 based on
Student’s t-test.
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354with poor outcomes [66,67], use of anti-VEGF agents should
be studied and considered.
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